SPONSORED:

House passes sweeping Pelosi bill to lower drug prices

The House on Thursday passed a sweeping bill aimed at lowering prescription drug prices, a step toward a long-held Democratic goal that was met with sharp Republican resistance.

The bill passed on a largely party-line vote of 230-192. The measure, which would allow the government to negotiate lower prices for prescription drugs, is one of House Democrats’ top priorities and is expected to be touted by vulnerable Democrats up for reelection next year.

The party is also looking to show that it is focused on kitchen table issues like lowering drug costs even as lawmakers prepare for an impeachment vote against President TrumpDonald TrumpNoem touts South Dakota coronavirus response, knocks lockdowns in CPAC speech On The Trail: Cuomo and Newsom — a story of two embattled governors McCarthy: 'I would bet my house' GOP takes back lower chamber in 2022 MORE.

ADVERTISEMENT

“What I hear most often is not impeachment, it's not what's on the front page of The Washington Post, it's ‘What are you going to do about the cost of our prescription drugs?’ ” said Rep. Kim SchrierKimberly (Kim) Merle SchrierDemocrats point fingers on whether Capitol rioters had inside help Rep. Kim Schrier defends Washington House seat from GOP challenger House approves .2T COVID-19 relief bill as White House talks stall MORE (D-Wash.), one of several freshmen facing competitive reelection races who showcased the bill on the Capitol steps Thursday. “And this bill is an answer to my constituents.”

Two Republicans voted in favor of the bill: Reps. Brian FitzpatrickBrian K. FitzpatrickTaylor Swift celebrates House passage of Equality Act Here are the three GOP lawmakers who voted for the Equality Act House passes sweeping protections for LGBTQ people MORE (Pa.) and Jaime Herrera BeutlerJaime Lynn Herrera BeutlerActing chief acknowledges police were unprepared for mob Riot probe to likely focus on McCarthy-Trump call Congressional Democrats say Trump acquittal was foregone conclusion MORE (Wash.), both moderates who face competitive reelection races next year. No Democrats voted against the bill.

The measure drew support from progressives following months of negotiations that cleared the way for it to pass this week. The bill is almost certain to die in the GOP-led Senate, though, given that Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellThe bizarre back story of the filibuster The Bible's wisdom about addressing our political tribalism Democrats don't trust GOP on 1/6 commission: 'These people are dangerous' MORE (R-Ky.) has called it “socialist” and vowed to block it. Republicans warn the measure would hinder the development of new treatments and impose “price controls.”

It is possible that smaller measures to lower drug prices could become law, given a bipartisan push to do something on the topic, but a path forward remains unclear amid division and multiple competing proposals.

Pelosi had tried for months to win Trump’s support for the bill, given that he broke from Republican orthodoxy and supported government negotiation on drug prices during his 2016 campaign.

After months of talks between Pelosi’s staff and the White House, though, the administration came out against the measure, leading Democrats to say Trump is breaking his promise to support negotiation for lower prices.

ADVERTISEMENT

“It’s exactly what President Trump promised on the campaign trail,” said Rep. Andy LevinAndrew (Andy) LevinDemocrats unveil bill to end tax break for investment managers Foreign adversaries skewer US after Capitol riots Biden taps Boston Mayor Marty Walsh for Labor secretary: report MORE (D-Mich.).

Trump is instead supporting a more modest bipartisan bill in the Senate to lower drug prices, legislation that does not include a provision to negotiate prices.

The House bill, known as the Elijah E. Cummings Lower Drug Costs Now Act, is named for the late Democratic lawmaker who was a champion of lowering drug prices.

The legislation would allow the secretary of Health and Human Services to negotiate lower prices for a minimum of 50 drugs per year, up to a maximum of 250 drugs. The prices for those drugs would also be capped at 120 percent of the prices in certain other wealthy countries. The government would then negotiate to bring prices down even further below that cap.

The lower prices would apply to people on private insurance in addition to those on Medicare.

If a drug company refused to negotiate, the company would be hit with a tax up to 95 percent of the revenue for the drug.

That steep penalty has led Republicans to argue the bill is not really “negotiation” as Democrats claim, but is effectively just mandating the price that drug companies must sell their products at.

The White House said the bill would impose “price controls” in its message threatening to veto the measure.

Progressive House Democrats had resisted the bill from the other direction, arguing that the measure did not go far enough. Reps. Pramila JayapalPramila JayapalProgressives fume over Senate setbacks House Democrats pass sweeping .9T COVID-19 relief bill with minimum wage hike Budget Committee chair pledges to raise minimum wage: 'Hold me to it' MORE (D-Wash.) and Mark PocanMark William PocanDemocrats don't trust GOP on 1/6 commission: 'These people are dangerous' Senate Democrats likely to face key test of unity on 2022 budget Democrats blast Facebook over anti-vaccine pages MORE (D-Wis.), along with Rep. Lloyd DoggettLloyd Alton DoggettHouse panel advances portion of relief package that includes ,400 checks Democrats urge repeal of business loss tax breaks in relief package Pediatrician killed in hostage situation at Texas medical center MORE (D-Texas), spent months pushing Pelosi to make the bill tougher.

In recent days they threatened to try to block a vote on the bill unless changes were made, but struck a deal with Pelosi after a meeting in the Speaker’s office Tuesday, clearing the way for the bill to pass with minimal drama. One of the changes increased the minimum number of drugs to be negotiated from 35 to 50.

The Congressional Budget Office (CBO) found the bill would lower prices by about 50 percent for drugs subject to negotiation and save $456 billion over 10 years. The bill then invests those savings in expanding Medicare benefits to include hearing, dental and vision care.

On the other hand, the CBO also found the bill would result in eight fewer drugs being developed over a decade, out of about 300 usually introduced in that time period. 

ADVERTISEMENT

House Republicans put forward a competing proposal that also received a vote Thursday. Their bill is much smaller in scale. Republicans touted it as leading to lower prices without imposing “price controls” or threatening the development of new drugs. 

House Minority Leader Kevin McCarthyKevin McCarthyMcCarthy: 'I would bet my house' GOP takes back lower chamber in 2022 Democrats don't trust GOP on 1/6 commission: 'These people are dangerous' Sunday shows preview: 2024 hopefuls gather at CPAC; House passes coronavirus relief; vaccine effort continues MORE (R-Calif.) called the Democratic bill a move to “appease the progressive base and have a partisan bill that denies us more cures,” while calling the GOP alternative a “practical solution” that would still allow new cures to come to market.

Democrats say polling shows the public is behind their bill. The progressive group Data for Progress on Thursday released polling testing different messages about the bill and finding strong support. Opposition never rose above 40 percent even when voters were presented with only negative messages about the bill. 

Pelosi said on the House floor on Thursday that she did not know why the White House stopped working with her on the drug pricing bill.

“We were working with the interests of the White House, the administration, on all of this,” she said. “I don't where it happened, but somewhere along the way, negotiation and the rest fell by the by. And what that could be attributed to, I don't know what.”

Updated: 2:30 p.m.